Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Simvastatin in the Acute Respiratory Distress Syndrome

Tools
- Tools
+ Tools

McAuley, Daniel F., Laffey, John G., O'Kane, Cecilia M., Perkins, Gavin D., Mullan, Brian, Trinder, T. John, Johnston, Paul, Hopkins, Philip A., Johnston, Andrew J., McDowell, Cliona and McNally, Christine (2014) Simvastatin in the Acute Respiratory Distress Syndrome. New England Journal Of Medicine , 371 (18). pp. 1695-1703. doi:10.1056/NEJMoa1403285

[img]
Preview
PDF
WRAP-Simvastin-Acute-Syndrome-Perkins-2017.pdf - Accepted Version - Requires a PDF viewer.

Download (1017Kb) | Preview
Official URL: http://dx.doi.org/10.1056/NEJMoa1403285

Request Changes to record.

Abstract

BACKGROUND
Studies in animals and in vitro and phase 2 studies in humans suggest that statins may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment with simvastatin would improve clinical outcomes in patients with ARDS.
METHODS
In this multicenter, double-blind clinical trial, we randomly assigned (in a 1:1 ratio) patients with an onset of ARDS within the previous 48 hours to receive enteral simvastatin at a dose of 80 mg or placebo once daily for a maximum of 28 days. The primary outcome was the number of ventilator-free days to day 28. Secondary outcomes included the number of days free of nonpulmonary organ failure to day 28, mortality at 28 days, and safety.
RESULTS
The study recruited 540 patients, with 259 patients assigned to simvastatin and 281 to placebo. The groups were well matched with respect to demographic and baseline physiological variables. There was no significant difference between the study groups in the mean (±SD) number of ventilator-free days (12.6±9.9 with simvastatin and 11.5±10.4 with placebo, P=0.21) or days free of nonpulmonary organ failure (19.4±11.1 and 17.8±11.7, respectively; P=0.11) or in mortality at 28 days (22.0% and 26.8%, respectively; P=0.23). There was no significant difference between the two groups in the incidence of serious adverse events related to the study drug.
CONCLUSIONS
Simvastatin therapy, although safe and associated with minimal adverse effects, did not improve clinical outcomes in patients with ARDS. (Funded by the U.K. National Institute for Health Research Efficacy and Mechanism Evaluation Programme and others; HARP-2 Current Controlled Trials number, ISRCTN88244364.)

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Respiratory distress syndrome, Adult, Statins (Cardiovascular agents)
Journal or Publication Title: New England Journal Of Medicine
Publisher: Massachusetts Medical Society
ISSN: 0028-4793
Official Date: 30 October 2014
Dates:
DateEvent
30 October 2014Published
September 2014Available
Volume: 371
Number: 18
Page Range: pp. 1695-1703
DOI: 10.1056/NEJMoa1403285
Status: Peer Reviewed
Publication Status: Published
Funder: Medical Research Council (Great Britain) (MRC), National Institute for Health Research (Great Britain) (NIHR), Scotland. Chief Scientist Office (CSO), National Institute for Social Care and Health Research (Wales) (NISCHR), Northern Ireland. Public Health Agency. HSC Research & Development Division
Grant number: HRA_POR-2010-131(Northern Ireland. Public Health Agency)
Related URLs:
  • Other

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us